“While the weight loss results were impressive across the group, the cost and side effects remain important barriers for long ...

Billions of dollars in annual revenue and the health of millions of patients are at stake in a drug industry battle over who ...

Mounjaro, a weekly injection, targets GIP and GLP-1 hormones to enhance insulin release and appetite regulation, aiding ...

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Now, Eli Lilly, the largest pharmaceutical company in the world in terms of market capitalisation, has launched its own ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

Semaglutide, branded as Rybelsus, Wegovy or Mounjaro, most popularly identified by Ozempic (as branded by Danish pharma giant ...

Zerodha CEO Nithin Kamath described weight-loss drugs Ozempic and Mounjaro as near 'miracle drugs,' highlighting their ...

Local governments in Iowa would be prohibited from having diversity, equity and inclusion offices under legislation passed by ...

I've been following the developments around Ozempic and GLP-1 drugs with some interest for a while, and last week Eli Lilly launched its variant, Mounjaro, in India. Remember, India has the highest ...